• Home
• About Us

About Us

CellMosaic® Inc. is an Innovator and Leader in Bioconjugation and Crosslinking Technologies. 

CellMosaic® is a Massachusetts-based platform technology company dedicated to creating high-quality, innovative, and advanced bioconjugates. Bioconjugates are used broadly as research tools, diagnostic reagents, and a novel modality for drugs, such as antibody-drug conjugates (ADCs). Due to the complexities of the bioconjugation process and requirement of techniques across multidisciplinary fields, few companies can offer high-quality bioconjugation services and deliver high-quality bioconjugates. CellMosaic® was founded in 2008 by Dr. Huang to fill this gap, drawing on her extensive experience in bioconjugation, drug development, and manufacturing. 

Since its inception, CellMosaic® has invested significant research efforts into developing advanced conjugation processes, including controlled, site-specific, and single labeling methods.These processes can generate single-ratio conjugates with over 90% purity. Based on these technologies, CellMosaic® has built a successful custom conjugation service business, delivering more than 500 projects and 300 unique conjugates (as of March 2023) to customers across various fields. 

In late 2016, CellMosaic® began commercializing personalized™ conjugation kits (PerKit™). By Dec. 2017, the PerKit™ product line expanded to include antibody drug conjugate (ADC) and protein drug conjugate (PDC) kits, allowing customers to prepare high-quality conjugates in-house comparable to those made at CellMosaic®. For chemicals and conjugates used frequently by customers, CellMosaic® coffers them as reagent products. For more information, please visit our products and services page.

In early 2011, CellMosaic® began developing a new class of crosslinkers to address the challenges of labeling and conjugating hydrophobic compounds. The company pioneered the concept of using natural and edible sugar alcohol (SA) monomers to create new crosslinking reagents and polymer carriers, called AqueaTether® (AqT®), for conjugation and drug delivery. SA is structurally similar to polyethylene glycol (PEG), but offers several advantages, including improved hydrophilicity, loading capacity, versatility, and easy of customization. The AqT® platform is the most versatile in development. CellMosaic® is currently developing next-generation bioconjugation kits and products based on AqT^® linkers. This platform can also be used to develop enhanced therapeutics across a broad range of drug molecules and treatment indications, significantly accelerating drug discovery and delivering optimized drug entities for development. The AqT^® platform addresses complex issues of bioavailability, stability, and toxicity for small hydrophobic drugs and large biologics.

Over the years, CellMosaic® has developed other key technologies, including oxLink™ and sxLink™ for studying protein–protein interactions and NeIon™ for detecting and quantifying trace amounts of analytes by mass spectrometry. The company is currently developing products based on these technologies for R&D usage. For more information, please visit our technologies page. 

CellMosaic® currently organizes its business into four units to meet customers' demands for high-quality, innovative, and advanced bioconjugates:

1. Reagents/Kits: Including pre-made bioconjugates or labeled/modified molecules and kits for customers to prepare bioconjugates in house.

2. R&D Bioconjugation Services: custom bioconjugation services and standardized routine bioconjugation synthesis.

3. Contract Development and Manufacturing of Bioconjugate Drug and Diagnostic Conjugates (CDMO): Focus on process development, scale-up, and GLP/GMP manufacturing, including the development and manufacturing of ADC with clinically validated classical linkers.

4. AqT^® ADC Development and Manufacturing: Enabling customer to use innovative AqT® linkers for novel ADC development and manufacturing.